Wednesday, April 12, 2023 11:11:41 AM
Gary,
You know Kite was 700 employee company pre FDA approval before it was bought by Gilead for somewhere in between $10-15B. And this was all before they had any approvals and they were not generating any commercial revenue.
There are many business functions a company needs to thrive even for a single product biotech company where manufacturing may be outsourced. For example, simple things like: who gets dinged if FDA comes knocking after the quality control one day? How is CAPA handled on the NWBO side? Who manages the CRM and accounting for 100s of doses going out every month? How is training and awareness built outside the trial sites? Who works with hospital and reimbursement/private insurance administrators to handle contract and payment discussions? The list goes on!
You know Kite was 700 employee company pre FDA approval before it was bought by Gilead for somewhere in between $10-15B. And this was all before they had any approvals and they were not generating any commercial revenue.
There are many business functions a company needs to thrive even for a single product biotech company where manufacturing may be outsourced. For example, simple things like: who gets dinged if FDA comes knocking after the quality control one day? How is CAPA handled on the NWBO side? Who manages the CRM and accounting for 100s of doses going out every month? How is training and awareness built outside the trial sites? Who works with hospital and reimbursement/private insurance administrators to handle contract and payment discussions? The list goes on!
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
